The Precision Peptide Company (BPC) announced a strategic exclusive marketing partnership on May 8 with Mixed Martial Arts Group Limited (MMA), covering distribution of BPC's peptide product line through MMA's network of approximately 530,000 user profiles, 75,000 active students, and 800 verified gyms globally. The revenue-sharing arrangement splits net revenue 50/50 between the two companies for the first 12 months, then shifts to 75% BPC / 25% MMA for the remainder of the term. The deal taps into the broader consumer peptide wellness market projected to approach $300B (per the May 12 GlobeNewswire industry report) and signals the increasingly mainstream integration of peptide products into the combat-sports and broader athletic-performance distribution channels ahead of the July 23-24 PCAC meeting.
A May 12 GlobeNewswire industry report frames the consumer peptide wellness market as approaching $300B globally on accelerating mainstream demand for science-backed peptide products spanning energy, recovery, metabolism, healthy aging, fitness, and overall well-being. The report tracks the post-Category-2 commercial cycle for BPC-157, TB-500, GHK-Cu, sermorelin, and the broader peptide supplement and cosmeceutical landscape — including OMI Wellbeauty's hair-growth peptides, Neurogan's 2% GHK-Cu body care, Auro Wellness's copper tripeptide serum, and the early-stage longevity peptide programs at Hims & Hers and LifeMD. The framing arrives six weeks ahead of the FDA's PCAC July 23-24 meeting that will decide compounding-pharmacy status for seven additional peptides including Emideltide (DSIP), Semax, and Epitalon.
OMI Wellbeauty (founder Naomi Whittel) launched a Hair Growth Peptides supplement line in May 2026, anchored by the Intermediate Filament Peptide (IFP) — a bioactive peptide formulated to support keratin networks in hair follicles and collagen IV production at the root. The double-blind, placebo-controlled 90-day clinical study reported 47% reduction in hair shedding with no significant side effects. The launch sits alongside Neurogan's 2% GHK-Cu body care and Auro Wellness's copper-tripeptide serum as part of the cosmetic and consumer-supplement peptide wave that has been accelerating into the July 2026 PCAC meeting. Unlike compounded peptides, OMI's product is a dietary supplement — not an FDA-approved drug — but the clinical-evidence framing distinguishes it from the broader unregulated peptide-supplement market.